Diarrhea News and Research

Latest Diarrhea News and Research

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

21 Mar 2011

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

Genentech, a member of the Roche Group, today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.

21 Mar 2011

Aid delivery trickles in one week after Japanese quake, tsunami

"Across large parts of Japan stricken a week ago by a quake and tsunami, aid isn't getting through. Blizzards, impassible roads, worries over radiation exposure, fuel shortages and other logistical problems have stalled aid from getting to those who need it, even as officials have boosted the amount of food and other goods available to some easier-to-reach communities," the Wall Street Journal reports.

19 Mar 2011

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.

19 Mar 2011

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix® (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC).

18 Mar 2011

Expert discusses certain measures that can help prevent HAI spread

Healthcare-associated infections represent a growing concern for both patients and healthcare providers across the nation. The Centers for Disease Control and Prevention estimates that approximately 1.7 million HAIs occur each year and contribute to the death of 99,000.

17 Mar 2011

New lozenge clinical trial for dry mouth treatment

A clinical trial using an all-natural lozenge to treat dry mouth, a condition that impacts 40 percent of American adults, is under way at Georgia Health Sciences University College of Dental Medicine.

17 Mar 2011

Experimental vaccine against human norovirus generates strong, safe immune response in mice

Scientists have shown that an experimental vaccine against the human norovirus - the bug behind about 90 percent of highly contagious nonbacterial illnesses that cause diarrhea and vomiting - can generate a strong immune response in mice without appearing to cause the animals any harm.

16 Mar 2011

Optimer receives U.S. patent for fidaxomicin to treat CDI

Optimer Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office has issued U.S. Patent 7,906,489 which covers methods of Clostridium difficile infection treatment with fidaxomicin.

16 Mar 2011

FDA clears Intralytix phage-based EcoShield food safety product

Intralytix, Inc. announced today that it has received regulatory clearance from the Food and Drug Administration for its phage-based EcoShield food safety product, effective against E. coli O157:H7.

16 Mar 2011

Innovative strategies to reduce infections in health-care settings

Can probiotics prevent pneumonia in patients breathing with the help of ventilators? That's just one question researchers at Washington University School of Medicine in St. Louis hope to answer as part of innovative new studies to reduce infections in health-care settings.

15 Mar 2011

Scientists show how E. coli strain causes infection in individuals

Scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, have shown how the O157:H7 strain of Escherichia coli causes infection and thrives by manipulating the host immune response.

15 Mar 2011

Radiation exposure explained

Amidst threat of major nuclear accident in Japan, people are in a state of panic worldwide said Jerrold Bushberg, a medical physicist at UC Davis. Bushberg said Americans do not have a good knowledge of the science of radiation and tend to over-exaggerate the risks.

14 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease.

11 Mar 2011

Novartis new MS treatment receives Notice of Compliance in Canada

Novartis Pharmaceuticals Canada Inc. announced today that its new MS treatment, Gilenya, has received Notice of Compliance in Canada.

10 Mar 2011

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

10 Mar 2011

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.

10 Mar 2011

House Foreign Affairs Committee hears testimony on security, human rights, health in Democratic Republic of Congo

At a House Committee on Foreign Affairs hearing on Tuesday, Ben Affleck, the actor, writer and director, and "other witnesses urged the Obama administration to immediately appoint a special envoy" for the Democratic Republic of Congo, which is due for a national election in November, CNN reports.

10 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

Diarrhea News and Research

Latest Diarrhea News and Research

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

Aid delivery trickles in one week after Japanese quake, tsunami

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Expert discusses certain measures that can help prevent HAI spread

New lozenge clinical trial for dry mouth treatment

Experimental vaccine against human norovirus generates strong, safe immune response in mice

Optimer receives U.S. patent for fidaxomicin to treat CDI

FDA clears Intralytix phage-based EcoShield food safety product

Innovative strategies to reduce infections in health-care settings

Scientists show how E. coli strain causes infection in individuals

Radiation exposure explained

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

Novartis new MS treatment receives Notice of Compliance in Canada

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

House Foreign Affairs Committee hears testimony on security, human rights, health in Democratic Republic of Congo

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Innovation in neuroscience drug discovery - eBook eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Innovation in neuroscience drug discovery - eBook eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in